A new study reported that a urine-based diagnostic test can outperform MRI for monitoring low-risk prostate cancer in patients on active surveillance. The results were published in The Journal of Urology, positioning the approach as a non-invasive alternative to repeated imaging. The work suggests urine testing may provide a better signal for disease monitoring decisions in low-risk settings—an area where clinicians often balance avoiding overtreatment with early detection of progression. The core value proposition is simplifying follow-up and potentially reducing patient burden associated with repeated MRI. While clinical adoption will depend on prospective validation and reimbursement pathways, the immediate impact is a shift in how surveillance strategies could be evaluated by trialists and guideline committees. For the diagnostics industry, the finding strengthens the clinical case for urine-based molecular monitoring as a scalable option in risk-stratified prostate cancer pathways.